 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5390 News |  |
| «12345678910111213...6970» |
- Assessment of therapeutic antibody efficacy without the interference of murine Fc receptors allows for investigation of human antibody-dependent cellular cytotoxicity mediated by NK cells in the FcResolv (Section 10) - Mar 5, 2024 - Abstract #AACR2024AACR_5909;
Rituximab treatment was tested in two diffuse large B cell lymphoma PDX models. There was no difference in percent tumor growth inhibition between the FcResolv
- CTN001 / Centenaire Biosci
CTN001, a first Twin Fc-immune cell engager, with a superior potency against Her2+ and Her2-low cancers by engaging multiple Fc-mediated mechanisms (Section 6) - Mar 5, 2024 - Abstract #AACR2024AACR_5535;
Consistently, CTN001 showed better anti-tumor efficacy than trastuzumab or its combination with pertuzumab in Her2+ tumor xenograft model and, surprisingly, even in Her2-low or resistant models. These results suggest that CTN001 can provide new therapeutic options for treating Her2-low patients differentiated from antibody-drug conjugates (ADCs), and that the Twin Fc-ICE can be an innovative platform to overcome limitations of existing therapeutics.
- SHR-4602 / Jiangsu Hengrui Pharma
SHR-4602, next generation of HER2-targeting ADC with potent anti-tumor efficacy overcoming the resistance of HER2 ADC with Topo I inhibitor payload in xenograft models (Section 23) - Mar 5, 2024 - Abstract #AACR2024AACR_5329;
P1
SHR-4602 represents a new generation HER2-targeting ADC to deliver a potent cytotoxin to HER2 expressing tumor cells and may be more efficacious to the tumors in which current anti-HER2 therapies are ineffective. SHR-4602 is now in the phase I clinical development stage for advanced malignant solid tumors (NCT05819684).
- CTN001 / Centenaire Biosci, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Twin Fc-immune cell engager (ICE): A novel antibody platform for cancer immunotherapy with enhanced avidity for Fc? receptors and complement (Section 23) - Mar 5, 2024 - Abstract #AACR2024AACR_5324;
The serum half-life of CTN001 at 10 mg/kg intravenous dose in rats is found non-inferior to that of trastuzumab (~12 days versus ~7 days). Taken together, Twin Fc-ICE provides an optimized platform with drug-like properties, which leverages avidity effects of Fc to potentiate therapeutic efficacy of antibody.
- Clinical efficacy and safety of HER2 targeted therapy in patients with metastatic colorectal cancer: A systematic review and meta-analysis (Section 46) - Mar 5, 2024 - Abstract #AACR2024AACR_5145;
Systematic review identified 9 study cohorts which were utilized in the meta-analysis, encompassing a total of 279 patients with mCRC who received Trastuzumab (T) in combination with either Pertuzumab (P), Tucatinib (Tu), Pyrotinib (Py), or Lapatinib (L). Overall, this comprehensive meta-analysis confirms that dual HER2 targeting therapies yield meaningful clinical efficacy, with favorable safety profiles, and improve outcomes in patients with RAS-WT HER2-positive mCRC.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Comparative spatial transcriptomic analysis of monoclonal antibodies targeting the same molecule: A comparison between cetuximab and panitumumab (Section 34) - Mar 5, 2024 - Abstract #AACR2024AACR_4806;
In the examination of the distribution patterns of two distinct therapeutic antibodies targeting EGFR within cancer tissues, a notable observation was made: while the cell types exhibited similarity, the associated genes demonstrated divergence, with different degrees of alignment with the intended target. This analytical approach, scrutinizing the distribution of different antibodies within tissue sharing a common target, holds promise as a widely applicable method for elucidating divergent therapeutic effects.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Tumor informed circulating tumor DNA monitoring for early treatment response and survival outcomes on trastuzumab + pertuzumab (Ballroom 6 CF - Upper Level - Convention Center) - Mar 5, 2024 - Abstract #AACR2024AACR_3314;
P2
Tumor-informed ctDNA monitoring provides insight into early treatment response and survival outcomes in patients with diverse HER2 amplified or mutated tumors receiving HER2 targeted therapy. On-treatment ctDNA dynamics refine and can potentially detect response/progression ahead of standard of care response assessments, suggesting early ctDNA monitoring as a valuable complementary tool for real-time treatment response monitoring.
- Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Temporal trends and disparities by race and ethnicity in treatment of women diagnosed with advanced hormone receptor-positive breast cancer: A SEER-Medicare analysis (Section 33) - Mar 5, 2024 - Abstract #AACR2024AACR_3062;
Among patients with HR+/HER2+ BC, rates of initiating pertuzumab and trastuzumab with chemotherapy increased while rates of trastuzumab with chemotherapy declined. The observed differential management of NHB and Hispanic compared with NHW patients with HR+/HER2+ BC using pertuzumab and trastuzumab with chemotherapy and AIs alone requires further investigation.
- | Perjeta (pertuzumab) / Roche
Journal, Metastases: Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy. (Pubmed Central) - Mar 5, 2024
In this report, we present two exceptional responses in hormone receptor-positive, HER2-nonamplified, HER2/HER3 co-mutated metastatic breast cancer patients who were treated with the anti-HER2-directed monoclonal antibodies, trastuzumab and pertuzumab. Both patients acheived exceptional responses to treatment, suggesting that combined trastuzumab, pertuzumab, and endocrine therapy could be a highly effective therapy for these patients and our observations could help prioritize trastuzumab deruxtecan as an early therapeutic choice for patients whose cancers have activating mutations in HER2.
- || Perjeta (pertuzumab) / Roche
P1 data, Journal: First-in-Human Evaluation of Site-Specifically Labeled Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer. (Pubmed Central) - Mar 4, 2024
Both patients acheived exceptional responses to treatment, suggesting that combined trastuzumab, pertuzumab, and endocrine therapy could be a highly effective therapy for these patients and our observations could help prioritize trastuzumab deruxtecan as an early therapeutic choice for patients whose cancers have activating mutations in HER2. The average effective dose for 89Zr-ss-pertuzumab was 0.54?
- | Piqray (alpelisib) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, Metastases: EPIK-B2: Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (clinicaltrials.gov) - Mar 2, 2024
P3, N=20, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
The average effective dose for 89Zr-ss-pertuzumab was 0.54? Trial completion date: Apr 2024 --> Sep 2024 | Trial primary completion date: Apr 2024 --> Sep 2024
- | taselisib (GDC-0032) / Roche
Trial completion date, Combination therapy, Metastases: Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer (clinicaltrials.gov) - Mar 2, 2024
P1, N=68, Active, not recruiting, Sponsor: Otto Metzger, MD
Trial completion date: Apr 2024 --> Sep 2024 | Trial primary completion date: Apr 2024 --> Sep 2024 Trial completion date: Dec 2023 --> May 2024
- | Perjeta (pertuzumab) / Roche
Journal, Combination therapy: A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer. (Pubmed Central) - Feb 26, 2024
P3
Domestic dual-target HP has a more satisfactory efficacy and safety in the neoadjuvant phase of treatment. https://clinicaltrials.gov/study/NCT05985187, NCT05985187.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Phase classification, Trial completion date, Trial primary completion date, Metastases: Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Feb 26, 2024
P1/2, N=72, Active, not recruiting, Sponsor: Fudan University
https://clinicaltrials.gov/study/NCT05985187, NCT05985187. Phase classification: P2 --> P1/2 | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Trial completion date, Trial primary completion date, Metastases: YOUNGBC-21: Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab (clinicaltrials.gov) - Feb 26, 2024
P=N/A, N=333, Completed, Sponsor: Fudan University
Phase classification: P2 --> P1/2 | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025 Active, not recruiting --> Completed | Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: May 2023 --> Sep 2023
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Trial withdrawal, Trial primary completion date: A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer (clinicaltrials.gov) - Feb 25, 2024
P3, N=0, Withdrawn, Sponsor: Henan Cancer Hospital
Active, not recruiting --> Completed | Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: May 2023 --> Sep 2023 N=456 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2024 --> Mar 2023
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, Journal: Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade. (Pubmed Central) - Feb 24, 2024
Conversely, in ER-positive cases, low ER expression, HER2 IHC 3+, and numerical TIL levels or high TIL levels emerged as independent predictors of pCR. Our results suggest that ER expression, HER2 protein expression, and TIL levels serve as valuable predictors of the treatment response to neoadjuvant TCHP.
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
Review, Journal: Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer. (Pubmed Central) - Feb 24, 2024
The HER2-targeted antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) represent a novel class of therapeutics in breast cancer...Clinical trials are crucial in determining the optimal dosing regimens, understanding resistance mechanisms, and identifying patient populations that would derive the most benefit from these treatments. These novel ADCs are at the forefront of a new era in targeted cancer therapy, holding the potential to improve outcomes for patients with HER2-positive and HER2-Low breast cancer.
- | Phase classification, Tumor mutational burden, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Feb 22, 2024
P2, N=673, Completed, Sponsor: Genentech, Inc.
These novel ADCs are at the forefront of a new era in targeted cancer therapy, holding the potential to improve outcomes for patients with HER2-positive and HER2-Low breast cancer. Phase classification: P2a --> P2
- || Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: CHERRY-PICK: Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade (clinicaltrials.gov) - Feb 21, 2024
P2, N=63, Not yet recruiting, Sponsor: Latin American Cooperative Oncology Group
Phase classification: P2a --> P2 Trial completion date: Jul 2031 --> Oct 2031 | Trial primary completion date: Jul 2026 --> Oct 2026
- | Perjeta (pertuzumab) / Roche
Preclinical, Journal: Evaluation of 177Lu-Labeled Pertuzumab F(ab')2 Fragments for HER2-Positive Cancer Targeting: A Comparative In Vitro and In Vivo Study. (Pubmed Central) - Feb 20, 2024
The radioformulation of [177Lu]Lu-DTPA-F(ab')2-pertuzumab holds great promise as a targeted approach for addressing HER2-positive cancers. A potentially effective strategy to amplify therapeutic efficacy involves dual epitope targeting by combining radiolabeled pertuzumab with cold trastuzumab.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date: Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer (clinicaltrials.gov) - Feb 20, 2024
P2, N=88, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A potentially effective strategy to amplify therapeutic efficacy involves dual epitope targeting by combining radiolabeled pertuzumab with cold trastuzumab. Trial completion date: Dec 2024 --> May 2025
- ||| Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Enrollment open, Combination therapy: DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer (clinicaltrials.gov) - Feb 20, 2024
P2, N=80, Recruiting, Sponsor: RemeGen Co., Ltd.
Trial completion date: Dec 2024 --> May 2025 Not yet recruiting --> Recruiting
- | Journal: Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC. (Pubmed Central) - Feb 19, 2024
Not yet recruiting --> Recruiting Positron emission tomography (PET) imaging ([89Zr]-panitumumab and [89Zr]-pertuzumab) was used to characterize EGFR and HER2 in HNSCC cell line
- | Perjeta (pertuzumab) / Roche, Trazimera (trastuzumab-qyyp) / Pfizer
Biomarker, Trial completion date: NCI-2016-00570: Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer (clinicaltrials.gov) - Feb 19, 2024
P2, N=18, Active, not recruiting, Sponsor: City of Hope Medical Center
Positron emission tomography (PET) imaging ([89Zr]-panitumumab and [89Zr]-pertuzumab) was used to characterize EGFR and HER2 in HNSCC cell line Trial completion date: Dec 2023 --> Dec 2024
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Correlation Between Machine Learning-based Characterization of HER2 Protein Expression by Immunohistochemistry and Response to Neoadjuvant Treatment in HER2+ Breast Cancer (Exhibit Hall; Poster Board Number: 28) - Feb 18, 2024 - Abstract #USCAP2024USCAP_2199;
P1
ML-based analysis of HER2 expression by IHC can capture the diverse HER2 staining intensities and patterns observed across tumors. The cell-level characterization and quantification of HER2 IHC may enable the prediction of pCR in HER2+ breast cancer patients receiving preoperative HER2-directed therapy plus chemotherapy.
- |||| Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: PATINA: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (clinicaltrials.gov) - Feb 15, 2024
P3, N=496, Active, not recruiting, Sponsor: Alliance Foundation Trials, LLC.
The cell-level characterization and quantification of HER2 IHC may enable the prediction of pCR in HER2+ breast cancer patients receiving preoperative HER2-directed therapy plus chemotherapy. Trial primary completion date: Dec 2023 --> Apr 2024
- || HER-2 pulsed DC1 / ImmunoRestoration
Trial completion date, Trial primary completion date: NATASHA: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab (clinicaltrials.gov) - Feb 15, 2024
P2, N=53, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Dec 2023 --> Apr 2024 Trial completion date: Oct 2025 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Jan 2025
- ||| Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: KATE3: A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) (clinicaltrials.gov) - Feb 15, 2024
P3, N=96, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Oct 2025 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Jan 2025 Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Metastases: APTneo: Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (clinicaltrials.gov) - Feb 15, 2024
P3, N=650, Active, not recruiting, Sponsor: Fondazione Michelangelo
Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Apr 2024 Trial completion date: Jun 2027 --> Mar 2027
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Surgery, Metastases: SWOG S1613: S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 15, 2024
P2, N=240, Active, not recruiting, Sponsor: SWOG Cancer Research Network
Trial completion date: Jun 2027 --> Mar 2027 Trial completion date: Jun 2024 --> Nov 2024
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date: Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer (clinicaltrials.gov) - Feb 15, 2024
P2, N=88, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Jun 2024 --> Nov 2024 Trial completion date: Dec 2023 --> Dec 2024
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Metastases: A Case of HER2-Positive Advanced Breast Cancer Who Was Able to Start and Continue Chemotherapy Despite Liver Damage Due to Diffuse Liver Metastasis (Pubmed Central) - Feb 6, 2024
Currently, chemotherapy has been switched to docetaxel (DTX)due to peripheral neuropathy caused by PTX, and treatment is continuing. In the case of HER2-positive breast cancer, good disease control may be achieved with aggressive treatment and intervention under dose adjustment and careful systemic management, even in the setting of liver injury.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: A Case of pagetoid Carcinoma of the Breast with Pathological Complete Response by Neoadjuvant Chemotherapy (Pubmed Central) - Feb 6, 2024
After neoadjuvant chemotherapy(pertuzumab, trastuzumab, and docetaxel, followed by adriamycin and cyclophosphamide), a pathological complete response was achieved. The patient was treated with anti-HER2 therapy without recurrence.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial completion date, FDG PET: PHERGain: Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (clinicaltrials.gov) - Feb 6, 2024
P2, N=377, Active, not recruiting, Sponsor: MedSIR
The patient was treated with anti-HER2 therapy without recurrence. Completed --> Active, not recruiting | Trial completion date: Nov 2023 --> Nov 2026
- | Perjeta (pertuzumab) / Roche
Journal, Metastases: Advanced Breast Cancer Guidelines in Latin America: Assessment, Adaptation, and Implementation of Fifth Advanced Breast Cancer Consensus Guidelines. (Pubmed Central) - Feb 5, 2024
Completed --> Active, not recruiting | Trial completion date: Nov 2023 --> Nov 2026 Despite the great relevance of the recommendations of the ABC5 consensus guidelines, we highlight that we still need to improve access for all patients, regardless of the country or health system they are in, for which we call to action to policy makers and patient groups to improve clinical outcomes of patients with advanced breast cancer in our region.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Age-related and organ-specific host mosaicism as a driver of dormant cancer cell awakening (Room 28 - Upper Level - Convention Center) - Feb 5, 2024 - Abstract #AACR2024AACR_1235;
We also tested whether CH can accelerate dormant DCC awakening in a murine model of CH carrying mutations in DNMT3A (KO or point mutation) and HER2+ mammary cancer. We propose our work may provide unprecedented insights into how a traceable age-related-mosaicism in the bone marrow (CH) may shape distant organs to be drive metastatic relapse.
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Journal, Heterogeneity: HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial. (Pubmed Central) - Feb 1, 2024
P2
HER2-targeting antibodies have limited efficacy in HET tumors. Our results support the stratification of patients based on HET status and the use of agents that target downstream components of the ERBB signaling pathway in patients with HET tumors.
- | Perjeta (pertuzumab) / Roche
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore. (Pubmed Central) - Jan 30, 2024
The ICER was most sensitive to the pCR rate, and the probabilistic sensitivity analysis showed that add-on pertuzumab had an 81.3% probability of being cost-effective at a willingness-to-pay threshold of S$45,000/QALY gained. This model demonstrated that the long-term clinical impact of early pertuzumab use, particularly the avoidance of metastatic disease and thus avoidance of higher costs and mortality rates, make neoadjuvant pertuzumab a cost-effective option in the management of patients with HER2+ breast cancer in Singapore.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Development of immunoliposomes containing cytotoxic gold payloads against HER2-positive breast cancers. (Pubmed Central) - Jan 29, 2024
Moreover, the fluorescently-labeled phosphane drug [AuCl(PPh-BODIPY)] (3) was encapsulated in both larger (Immunolipo-Tras-3) and smaller (Opt-Immunolipo-Tras-3) immunoliposomes and used to visualize the intracellular localization of the payload. Fluorescent imaging studies found that Opt-Immunolipo-Tras-3 accumulates in the cells more than 3 and that the unencapsulated payload accumulates primarily in lysosomes, while targeted liposomal 3 localizes in mitochondria and ER, hinting at different possibilities for modes of action.
- | Perjeta (pertuzumab) / Roche
Journal: Mass Spectrometric ITEM-ONE and ITEM-TWO Analyses Confirm and Refine an Assembled Epitope of an Anti-Pertuzumab Affimer. (Pubmed Central) - Jan 27, 2024
The experimentally determined apparent enthalpy (?Hm0g#) and apparent free energy (?Gm0g#) of the complex dissociation reaction indicate that the opposite reaction-complex formation-is spontaneous at room temperature. Due to strong binding to Pertuzumab and because of recognizing Pertuzumab's unique partial amino acid sequences, the anti-Pertuzumab affimer 00557_709097 is considered excellently suitable for implementation in Pertuzumab quantitation assays as well as for the accurate therapeutic drug monitoring of Pertuzumab in biological fluids.
- Herceptin (trastuzumab) / Roche
RECHALLENGING WITH TRASTUZUMAB AFTER RECOVERING FROM CHEMOTHERAPY INDUCED HEART FAILURE (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_3319;
Trastuzumab primarily leads to myocardial dysfunction and it has high probability of being reversible. In some cases, it may be necessary to discontinue or pause trastuzumab treatment and initiate heart failure guideline directed medical therapy to mitigate effects of cardiotoxicity.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Surgery, Metastases: Primary site surgery of de novo stage IV HER2-positive breast cancer in the era of new drug treatments. (Pubmed Central) - Jan 24, 2024
Primary site surgery does not improve the prognosis of de novo stage IV HER2-positive breast cancer. In the era of anti-HER2 therapy, primary surgery is not recommended, except in exceptional circumstances.
- || TAEK-VAC-HerBy vaccine / Bavarian Nordic
Enrollment closed, Combination therapy, Metastases: TAEK-VAC-HerBy-001: TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer (clinicaltrials.gov) - Jan 23, 2024
P1, N=55, Active, not recruiting, Sponsor: Bavarian Nordic
In the era of anti-HER2 therapy, primary surgery is not recommended, except in exceptional circumstances. Recruiting --> Active, not recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, Journal, Gene Signature: Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial. (Pubmed Central) - Jan 22, 2024
Basal single-subtype tumors exhibit an inferior prognosis compared with other subgroups and may be candidates for additional therapeutic strategies. Preliminary results suggest patients with HER2-positive, genomically HER2 single-subtype tumors may particularly benefit from added pertuzumab, which warrants further investigation.
- Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINYBreast03, a randomised, open-label, phase 3 trial () - Jan 22, 2024 - Abstract #YIR2024YIR_126;
P3
Trastuzumab deruxtecan showed a significant improvement in overall survival versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer, as well as the longest reported median progressionfree survival, reaffirming trastuzumab deruxtecan as the standard of care in the second-line setting. A manageable safety profile of trastuzumab deruxtecan was confirmed with longer treatment duration.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Tukysa (tucatinib) / Pfizer
Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumabderuxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study. () - Jan 22, 2024 - Abstract #YIR2024YIR_115;
In this large retrospective cohort, TTC shows significant efficacy for patients with HER2+ MBC previously exposed to T-DXd. Data and subgroup analyses will be updated for the meeting.
- Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab, and Pertuzumab in Hormone Receptor (HR)-Positive, HER2-Positive Metastatic Breast Cancer (ASPIRE) () - Jan 22, 2024 - Abstract #YIR2024YIR_111;
The combination provides a chemotherapy-free alternative for pts with triple positive breast cancers. Further follow up will determine impact on PFS Table 1.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results () - Jan 22, 2024 - Abstract #YIR2024YIR_94;
Notably, HER2 amplification level had a predictive role regardless of IHC results. Even in patients with HER2 protein expression of 3+, treatment outcome to HER2directed therapy was dependent on the level of HER2 gene amplification.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data () - Jan 22, 2024 - Abstract #YIR2024YIR_91;
P2
Patients with confirmed partial response or stable disease (?4 months) in the CNS had stable PROs over time. Pertuzumab plus highdose trastuzumab represents a reasonable non-chemotherapeutic treatment option for selected patients with HER2-positive MBC with CNS metastases.